Small molecules in treatment of sepsis

Current Drug Targets

Volumn 12, Issue 2, 2011, Pages 256-262

  Hu, Yan ^a   Xie, Guo Hao ^a   Chen, Qi Xing ^a   Fang, Xiang Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Adenosine receptors; C5a receptor; Caspases; Estrogen receptor ; Macrophage migration inhibitory factor; QseC signaling; Sepsis; Toll like receptor 4

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ANTIINFECTIVE AGENT; BOT 64; CASPASE; CASPASE INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; DS 96; ESTROGEN RECEPTOR BETA; EVK 203; ISO 1; LED 209; LIPOPOLYSACCHARIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; OXIM 11; PEPTOID 7; PLACEBO; PMX 53; POLYMYXIN B; RESATORVID; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VX 166; WAY 202196;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL GENE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN; PHAGOCYTOSIS; REVIEW; SALMONELLOSIS; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TULAREMIA; ANIMAL; ARTICLE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; SEPSIS;

EID: 79955666815     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011794182737     Document Type: Review

References (79)

1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31: 1250-56.
2. The EPISPESIS group. Episepsis: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580-8.
3. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-96.
4. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales and Northern Ireland. Crit Care Med 2003; 31: 2332-8.
5. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-18.
6. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
7. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010; 38: 1276-83.
8. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
9. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med 1999; 340: 1834-5.
10. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007; 375: 36-42.
11. Bozza FA, Gomes RN, Japiassu AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22: 309-13.
12. Hotchkiss RS, Tinsley KW, Karl IE. Role of apoptotic cell death in sepsis. Scand J Infect Dis 2003; 35: 585-92.
13. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230-51.
14. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15: 496-7.
15. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma 2005; 58: 867-74.
16. Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J Med 2009; 361: 2646-52.
17. Jorgensen WL. Efficient drug lead discovery and optimization. Acc Chem Res 2009; 42: 724-33.
18. Barcellos GB, Pauli I, Caceres RA, Timmers LF, Dias R, de Azevedo WF Jr. Molecular modeling as a tool for drug discovery. Curr Drug Targets 2008; 9: 1084-91.
19. Mandal S, Moudgil M, Mandal SK. Rational drug design. Eur J Pharmacol 2009; 625: 90-100.
20. Vesentini S, Soncini M, Zaupa A, Silvestri V, Fiore GB, Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part I: molecular interaction of polymyxin B with endotoxins. Int J Artif Organs 2006; 29: 239-50.
21. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-5.
22. Nguyen TB, Adisechan AK, Suresh Kumar EV, et al. Protection from endotoxic shock by EVK-203, a novel alkylpolyamine sequestrant of lipopolysaccharide. Bioorg Med Chem 2007; 15: 5694-709.
23. Sil D, Shrestha A, Kimbrell MR, et al. Bound to shock: Protection from lethal endotoxemic shock by a novel, nontoxic, alkylpolyamine lipopolysaccharide sequestrant. Antimicrob Agents Chemother 2007; 51: 2811-9.
24. Shrestha A, Li R, Sil D, et al. Pharmacokinetics of DS-96, an alkylpolyamine lipopolysaccharide sequestrant, in rodents. J Pharm Sci 2008; 97: 5376-85.
25. Mora P, Masip I, Cortés N, et al. Identification from a positional scanning peptoid library of in vivo active compounds that neutralize bacterial endotoxins. J Med Chem 2005; 48: 1265-8.
26. Vicent MJ, Cascales L, Carbajo RJ, Cortés N, Messeguer A, Pérez Payá E. Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins. J Control Release 2010; 142: 277-85.
27. Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6 R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits tolllike receptor 4-mediated cytokinen production through suppression of intracellular signaling. Mol Pharmacol 2006; 69: 1288-95.
28. Takashima K, Matsunaga N, Yoshimatsu M, et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 2009; 157:1250-62.
29. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Iizawa. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007; 571: 231-9.
30. Efficacy & Safety of TAK-242 in Adults with Severe Sepsis. Available at: http://clinicaltrials.gov/ct2/show/NCT00143611?term =TAK-242&rank=1 [accessed May 17, 2010].
31. Kim BH, Roh E, Lee HY, et al. Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta. Mol Pharmacol 2008; 73: 1309-18.
32. Ward PA. Role of the complement in experimental sepsis. J Leukoc Biol 2008; 83: 467-70.
33. Donnelly TJ, Meade P, Jagels M, et al. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med 1994; 22: 768-76.
34. Guo RF, Riedemann NC, Sun L, et al. Divergent signaling pathways in phagocytic cells during sepsis. J Immunol 2006; 177: 1306-13.
35. Brekke OL, Christiansen D, Fure H, Fung M, Mollnes TE. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coliinduced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human. J Leukoc Biol 2007; 81: 1404-13.
36. Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol 2008; 45: 1199-207.
37. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-77.
38. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429-48.
39. Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Investig 2002; 110: 101-8.
40. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5: 788-92.
41. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15: 568-70.
42. Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM. A new small molecule C5a receptor antagonist inhibits the Reverse-Passive Arthus Reaction and endotoxic shock in rats. J Immunol 2000; 164: 6560-5.
43. Morgan M, Bulmer AC, Woodruff TM, et al. Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. Eur J Pharm Sci 2008; 33: 390-8.
44. Blagg J, Mowbray C, Pryde DC, et al. Small, non-peptide C5a receptor antagonists: Part 1. Bioorg Med Chem Lett 2008; 18: 5601-4.
45. Blagg J, Mowbray C, Pryde D, et al. Small, non-peptide C5a receptor antagonists: Part 2. Bioorg Med Chem Lett 2008; 18: 5605-8.
46. Vergunst CE, Gerlag DM, Dinant H, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 2007; 46: 1773-8.
47. Available from: http://www.arana.com/inflammation_franchise_ pmx.htm [accessed May 17, 2010].
48. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 1996; 10: 1607-13.
49. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
50. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glicocorticoidinduced modulator of cytokine production. Nature 1995; 377: 68-71.
51. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-6.
52. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-70.
53. Crichlow GV, Lubetsky JB, Leng L, Bucala R, Lolis EJ. Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. Biochemistry 2009; 48: 132-9.
54. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996; 93: 5191-6.
55. Suzuki M, Sugimoto H, Nakagawa A, Tanaka I, Nishihira J, Sakai M. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol 1996; 3: 259-66.
56. Al-Abed Y, Dabideen D, Aljabari B, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005; 280: 36541-4.
57. Crichlow GV, Cheng KF, Dabideen D, et al. Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem 2007; 282: 23089-95.
58. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
59. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
60. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
61. Rasko DA, Moreira CG, Li de R, et al. Targeting QseC signaling and virulence for antibiotic development. Science 2008; 321: 1078-80.
62. Clarke MB, Hughes DT, Zhu C, Boedeker EC, Sperandio V. The QseC sensor kinase: A bacterial adrenergic receptor. Proc Natl Acad Sci USA 2006; 103: 10420-5.
63. Bearson BL, Bearson SM. The role of the QseC quorum-sensing sensor kinase in colonization and norepinephrine-enhanced motility of Salmonella enterica serovar Typhimurium. Microb Pathog 2008; 44: 271-8.
64. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci USA 2007; 104: 6037-42.
65. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-70.
66. Lee HT, Kim M, Joo JD, Gallos G, Chen JF, Emala CW. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006; 291:R959-69.
67. Németh ZH, Csóka B, Wilmanski J, et al. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol 2006; 1; 176: 5616-26.
68. Hubacek JA, Stüber F, Fröhlich D, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 29: 557-61.
69. Wichmann MW, Inthorn D, Andress HJ, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 2000; 26: 167-72.
70. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003; 144: 4241-9.
71. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008; 180: 630-6.
72. Cristofaro PA, Opal SM, Palardy JE, et al. WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med 2006; 34: 2188-93.
73. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1: 496-501.
74. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol 2008; 615: 13-23.
75. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 174: 5110-8.
76. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Rev Immunol 2006; 6: 813-22.
77. Catalan MP, Esteban J, Subirá D, Egido J, Ortiz A. Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int 2003; 23: 123-6.
78. Oberholzer C, Tschoeke SK, Moldawer LL, Oberholzer A. Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice. J Mol Med 2006; 84: 389-95.
79. Weber P, Wang P, Maddens S, et al. VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Crit Care 2009; 13: R146.